A research at U.S. Department of Energy’s (DOE) Brookhaven National Laboratory has concluded that Vigabatrin, a drug that can be used in treatment for drug addiction, causes rapid weight loss in animals. The medication induces satiety in non-obese animals as well as those bred to be obese, reducing their weight by 20%. Vigabatrin, currently, is in Phase II of the FDA-approved clinical trials as a treatment for cocaine and methamphetamine addiction. This drug will prove beneficial for both the severe form of obesity, that is genetic, and also for the obesity resulting from overeating, as this disorder is characterized by consumption patterns that are similar to drug-taking in those dependent on cocaine.